CoChat

Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels

Open access

The DOI matches its Crossref record; 58 of the 61 references it cites were found in a registry or an index.

Abstract

Chemoresistance is a major problem in the therapeutic management of pancreatic cancer, concurring to poor clinical outcome. A number of mechanisms have been proposed to explain resistance to gemcitabine, a standard of care for this malignancy, among which is included aberrant miRNA expression. In the current study, we investigated the role of miR-217, which is strongly down-regulated in cancerous, compared to normal, pancreatic tissues or cells, in sensitizing human pancreatic cancer cell lines to this drug. The low expression of miR-217 in pancreatic cancer patients was confirmed in two gene expression datasets (GSE41372 and GSE60980), and the prognostic value of two target genes (ANLN and TRPS1), was estimated on clinical data from the Tumor Cancer Genome Atlas (TCGA). Transfecting miR-217 mimic in pancreatic cancer cells reduced viability, enhanced apoptosis, and affected cell cycle by promoting a S phase arrest in gemcitabine-treated cells. Moreover, in drug-exposed cells subjected to miR-217 forced expression, a down-regulation for several genes involved in cancer drug resistance was observed, many of which are cell cycle regulators, such as CCND1, CCNE1, CDK2, CDKN1A, CDKN1B, while others, such as ARNT, BRCA1, BRCA2, ELK1, EGFR, ERBB4, and RARA are involved in proliferation and cell cycle progression. Our results support the notion that miR-217 enhances pancreatic cancer sensitivity to gemcitabine, mainly impairing cell cycle progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom11050639

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Volcano plot representation of the differentially expressed miRNAs between pancreatic cancer and normal tissue in GSE41372 and GSE60980 datasets (A). A VENN diagram showing the shared miR-217 target genes highly predicted and experimentally observed filtered from GSE41372 and GSE60980 datasets (B). Volcano plot representation of the differentially expressed mRNAs between pancreatic cancer and normal tissue in GSE41372 and GSE60980 datasets (C). Prognostic value of target mRNAs in pancreatic cancer versus normal tissues. Kaplan–Meier survival curves for 150 pancreatic cancer patients from TCGA dataset revealing that low expression levels of ANLN and TRPS1 are associated with a better probability of survival. Statistical differences were analyzed using the log-rank test (D).
Figure 1 Volcano plot representation of the differentially expressed miRNAs between pancreatic cancer and normal tissue in GSE41372 and GSE60980 datasets (A). A VENN diagram showing the shared miR-217 target genes highly predicted and experimentally observed filtered from GSE41372 and GSE60980 datasets (B). Volcano plot representation of the differentially expressed mRNAs between pancreatic cancer and normal tissue in GSE41372 and GSE60980 datasets (C). Prognostic value of target mRNAs in pancreatic cancer versus normal tissues. Kaplan–Meier survival curves for 150 pancreatic cancer patients from TCGA dataset revealing that low expression levels of ANLN and TRPS1 are associated with a better probability of survival. Statistical differences were analyzed using the log-rank test (D).CC BY · PubMed Central
Figure 2 The top ten enriched diseases and biological functions of miR-217 according to IPA Core Analysis (A). The network of canonical pathways (B) and the most represented canonical pathways (C) of miR-217 and its target genes, according to IPA Core Analysis. Grey bars represent pathways with no activity predicted due to a lack of information in the Ingenuity Pathway Knowledge Base (IPKB), despite highly significant association between genes and pathway. White bars represent pathways with z-score of 0, pointing out that differentially expressed genes did not indicate an evident prediction of activation or inhibition.
Figure 2 The top ten enriched diseases and biological functions of miR-217 according to IPA Core Analysis (A). The network of canonical pathways (B) and the most represented canonical pathways (C) of miR-217 and its target genes, according to IPA Core Analysis. Grey bars represent pathways with no activity predicted due to a lack of information in the Ingenuity Pathway Knowledge Base (IPKB), despite highly significant association between genes and pathway. White bars represent pathways with z-score of 0, pointing out that differentially expressed genes did not indicate an evident prediction of activation or inhibition.CC BY · PubMed Central
Figure 3 miR-217 endogenous expression in control HPDE cells and in BxPC-3 and PANC-1 PDAC cell lines. The relative miR-217 expression in the PDAC cell lines was much lower than that in the control cells (A). Dose-response (1 nM, 5 nM, and 10 nM) and time-course (24 h and 48 h) of miR-217 mimic transfection in BxPC-3 (B) and PANC-1 (C) cells (Log10 scale on the y-axis). *** p-values < 0.001.
Figure 3 miR-217 endogenous expression in control HPDE cells and in BxPC-3 and PANC-1 PDAC cell lines. The relative miR-217 expression in the PDAC cell lines was much lower than that in the control cells (A). Dose-response (1 nM, 5 nM, and 10 nM) and time-course (24 h and 48 h) of miR-217 mimic transfection in BxPC-3 (B) and PANC-1 (C) cells (Log10 scale on the y-axis). *** p-values < 0.001.CC BY · PubMed Central
Figure 4 Flow cytometric analysis of cell count and viability performed by using Muse Cell Analyzer in mock-transfected, AllStars-transfected and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Bar charts show the quantitative measurements expressed as mean ± SD of three independent experiments. Statistical differences were calculated by two-way ANOVA for the count of total and viable, and by one-way ANOVA for percentage of viability, respectively. p < 0.05 (*) and p < 0.01 (**).
Figure 4 Flow cytometric analysis of cell count and viability performed by using Muse Cell Analyzer in mock-transfected, AllStars-transfected and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Bar charts show the quantitative measurements expressed as mean ± SD of three independent experiments. Statistical differences were calculated by two-way ANOVA for the count of total and viable, and by one-way ANOVA for percentage of viability, respectively. p < 0.05 (*) and p < 0.01 (**).CC BY · PubMed Central
Figure 5 Flow cytometric analysis of apoptosis performed by using Muse Cell Analyzer in mock-transfected, AllStars-transfected, and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Tables show the quantitative measurements expressed as mean ± SD of three independent experiments. Statistical differences were calculated by two-way ANOVA, followed by post hoc Tukey’s multiple comparisons test.
Figure 5 Flow cytometric analysis of apoptosis performed by using Muse Cell Analyzer in mock-transfected, AllStars-transfected, and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Tables show the quantitative measurements expressed as mean ± SD of three independent experiments. Statistical differences were calculated by two-way ANOVA, followed by post hoc Tukey’s multiple comparisons test.CC BY · PubMed Central
Figure 6 Flow cytometric analysis of cell count and viability performed by using Muse Cell Analyzer in mock-transfected, AllStars-transfected, and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Bar charts show the quantitative measurements expressed as mean ± SD of three independent experiments. Statistical differences were calculated by two-way ANOVA, followed by post hoc Tukey’s multiple comparisons test.
Figure 6 Flow cytometric analysis of cell count and viability performed by using Muse Cell Analyzer in mock-transfected, AllStars-transfected, and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Bar charts show the quantitative measurements expressed as mean ± SD of three independent experiments. Statistical differences were calculated by two-way ANOVA, followed by post hoc Tukey’s multiple comparisons test.CC BY · PubMed Central
Figure 7 Clustergram representation of cancer drug resistance genes expression in mock-transfected and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Fold change of cancer drug resistance gene expression in miR-217-transfected versus mock-transfected BxPC-3 (C) and PANC-1 (D) cells. The plots show the means of two independent experiments for each cell lines. p < 0.05 (*) or p < 0.01 (**) or p < 0.001 (***).
Figure 7 Clustergram representation of cancer drug resistance genes expression in mock-transfected and miR-217-transfected BxPC-3 (A) and PANC-1 (B) cells alone, or upon gemcitabine treatment. Fold change of cancer drug resistance gene expression in miR-217-transfected versus mock-transfected BxPC-3 (C) and PANC-1 (D) cells. The plots show the means of two independent experiments for each cell lines. p < 0.05 (*) or p < 0.01 (**) or p < 0.001 (***).CC BY · PubMed Central
Figure 8 Interaction network between pancreatic adenocarcinoma signaling and gemcitabine pathway generated from IPA. Shared genes are red colored.
Figure 8 Interaction network between pancreatic adenocarcinoma signaling and gemcitabine pathway generated from IPA. Shared genes are red colored.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 58 references

Cited by

See all 26

Metadata

Authors
Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V.
Affiliations
Casa Sollievo della Sofferenza (IT)
Corresponding author
  • Binda, Elena
  • Pazienza, Valerio
Venue
Biomolecules
Publisher
MDPI AG
Published
2021-04-26
Volume
11
Issue
5
Pages
639
ISSN
2218-273X (ISSN-L)
OpenAlex
W3158790987
Cited by
26
References
61
Citations by year
2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 1
FWCI
1.79
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministero della Salute (Ricerca Corrente 2018-2020)
  • Associazione Italiana per la Ricerca sul Cancro (IG2019-ID23006)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
miR-217, gemcitabine, pancreatic cancer, chemoresistance, microRNA restoration, cell cycle arrest, S phase arrest, apoptosis, anillin, TRPS1, cell cycle regulators, drug sensitivity
MeSH terms
Gemcitabine, Cell Survival, Deoxycytidine, Humans, Pancreatic Neoplasms, Prognosis, Apoptosis, Cell Cycle Proteins, Drug Resistance, Neoplasm, Databases, Genetic, MicroRNAs, Cell Line, Tumor, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels. https://app.cochat.ai/papers/10.3390/biom11050639
The paper
Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V. (2021). Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels. Biomolecules. https://doi.org/10.3390/biom11050639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.